Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity-Reference-Cited by-同舟云学术

Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity

Published:2018-10-26 Issue:6 Volume:108 Page:600-611
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Ohtani Kisho,Fujino Takeo,Ide Tomomi,Funakoshi Kouta,Sakamoto Ichirou,Hiasa Ken-ichi,Higo Taiki,Kamezaki Kenjiro,Akashi Koichi,Tsutsui Hiroyuki

Funder

Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00392-018-1386-0.pdf

Reference38 articles.

1. Roboz GJ (2012) Current treatment of acute myeloid leukemia. Curr Opin Oncol 24(6):711–719. https://doi.org/10.1097/CCO.0b013e328358f62d

2. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. https://doi.org/10.1186/1471-2407-10-337

3. Oliveira GH, Mukerji S, Hernandez AV, Qattan MY, Banchs J, Durand JB, Iliescu C, Plana JC, Tang WH (2014) Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol 113(11):1893–1898. https://doi.org/10.1016/j.amjcard.2014.03.018

4. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342(15):1077–1084. https://doi.org/10.1056/NEJM200004133421502

5. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Authors/Task Force M, Guidelines ESCCfP (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801. https://doi.org/10.1093/eurheartj/ehw211

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Arrhythmia Risk after Anti-Cancer Drug Exposure and Related Disease Molecular Imaging Outlook: A Systematic Review, Meta-Analysis, and Network Meta-Analysis;Biology;2024-06-25

2. Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers;Biomedicines;2024-05-09

3. Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction;Current Heart Failure Reports;2024-05-02

4. Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights;Basic Research in Cardiology;2024-02-14

5. The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes;Current Oncology;2024-01-24